TopoTarget completes the capital increase and the acquisition of Apoxis SA
29-Jun-2007
The two lead oncology products being developed by Apoxis are: APO010, a human FAS-ligand protein product generated via Apoxis' MegaLigandTM proprietary protein research technology platform in Phase I, and APO866, a small molecule therapeutic inhibiting the NAD+ production.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.